// App-Quantinova.ai

5569 : A Randomized, Open-Label, Phase 2 Study of Anti-NaPi2b Antibody-Drug Conjugate (ADC) Lifastuzumab (Lifa) Vedotin (DNIB0600A) Compared to Pegylated Liposomal Doxorubicin (PLD) in Patients (Pts) with Platinum-Resistant Ovarian Cancer (PROC).

Researchers

Presenter

  • Susana N. Banerjee

Principal Investigators

  • Michael J. Birrer

  • Erika Paige Hamilton

  • Jurjees Hasan

  • Alexandra Leary

  • Kathleen N. Moore

  • Beata Mackowiak-Matejczyk

  • Joanna Pikiel

  • Isabelle Ray-Coquard

  • Peter Trask

  • Kedan Lin

  • Anjali Vaze

  • Youn Jeong Choi

  • Jim Marsters

  • Daniel J. Maslyar

  • Vanessa Lemahieu

  • Yulei Wang

  • Eric William Humke

  • Joyce F. Liu

Medical Centers

  • The Royal Marsden Hospital, London, United Kingdom

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • Massachusetts General Hospital Cancer Center, Boston, MA

  • Sarah Cannon Research Institute/Tennessee Oncology, Brentwood, TN

  • The Christie Hospital, Manchester, United Kingdom

  • Gustave Roussy Cancer Campus, Villejuif, France

  • University of Oklahoma Health Sciences Center, Oklahoma City, OK

  • Bialystok Oncology Center, Bialystok, Poland

  • Wojewodzkie Centrum Onkologii, Gdansk, Poland

  • Centre Leon Berard, Lyon, France

  • Genentech, Inc., South San Francisico, CA

  • Genentech, Inc., Foster City, CA

  • Genentech, Inc., Redwood, CA

  • Roche/Genentech, South San Francisco, CA

  • Dana-Farber Cancer Institute, Boston, MA

Locations

  • Canada

  • Poland

  • United Kingdom

  • United States

  • France

Companies

  • Genentech, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Genetic Disorder

Disease

  • Gynaecological cancer

Biomarkers

  • Apparent diffusion coefficient

Drug/Treatment

  • Doxorubicin Hydrochloride

  • Lifastuzumab vedotin

Outcome

  • Positive

Study Design

  • Randomized

  • Open Label

Phase

  • II

Study Id's

  • NCT01991210

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved